Puja Whitlow, MD

Staff Physician, Division of Oncology

Assistant Professor, UC Department of Pediatrics

Phone 513-636-0670

Email puja.whitlow@cchmc.org

Supportive care: nutrition and quality of life

Dr. Puja Whitlow, MD, received a Bachelor of Arts in religious studies and biology from Indiana University in 1999, and then obtained a Doctor of Medicine from Indiana University School of Medicine in 2003. She completed a residency in pediatrics and a fellowship in pediatric hematology-oncology at the University of Texas Southwestern Medical School. In 2013, she was granted an Arizona Clinical and Translational Research Graduate Certificate. She is certified in pediatrics and in pediatric hematology-oncology by the American Board of Pediatrics.

Dr. Whitlow was awarded the Hyundai Hope on Wheels grant in 2011 for a clinical trial involving the effect of EMLA cream application in pediatric leukemia patients undergoing general anesthesia for a lumbar puncture.

BA: Religious Studies and Biology, Indiana University, Bloomington, IN, 1995-1999.

MD: Indiana University School of Medicine, Indianapolis, IN, 1999-2003.

Residency: Pediatrics, University of Texas Southwestern Medical Center, Children's Medical Center, Dallas, TX, 2003-2006.

Fellowship: Pediatric Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 2007-2010.

Arizona Clinical & Translational Research Graduate Certificate: University of Arizona, Mel & Enid Zuckerman College of Public Health, Tucson, AZ, 2011-2013.

Certification: American Board of Pediatrics, Pediatrics, 2006; American Board of Pediatrics, Pediatric Hematology-Oncology, 2011.

Kopp L, Gupta, P, Pelayo-Katsanis L, Wittman B, Katsanis E. Long-Term Complications in Pediatric Cancer Survivors. Am Journal Med. 2012; 125:636-41.

Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Brekken RA, Loizos N. Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGRR α Expression in Lung Cancer Xenografts. Mol Cancer Ther. 2012; 11:2473-82.